Poland
· Delayed Price · Currency is PLN Bioceltix Statistics
Total Valuation
Bioceltix has a market cap or net worth of PLN 467.82 million. The enterprise value is 430.57 million.
| Market Cap | 467.82M |
| Enterprise Value | 430.57M |
Important Dates
The next estimated earnings date is Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bioceltix has 4.92 million shares outstanding. The number of shares has increased by 7.65% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.92M |
| Shares Change (YoY) | +7.65% |
| Shares Change (QoQ) | +6.02% |
| Owned by Insiders (%) | 7.43% |
| Owned by Institutions (%) | 18.46% |
| Float | 3.83M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 11.29 |
| P/TBV Ratio | 11.29 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -27.52 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -23.25 |
Financial Position
The company has a current ratio of 15.51, with a Debt / Equity ratio of 0.02.
| Current Ratio | 15.51 |
| Quick Ratio | 15.50 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.05 |
| Interest Coverage | -135.06 |
Financial Efficiency
Return on equity (ROE) is -56.22% and return on invested capital (ROIC) is -34.66%.
| Return on Equity (ROE) | -56.22% |
| Return on Assets (ROA) | -32.11% |
| Return on Invested Capital (ROIC) | -34.66% |
| Return on Capital Employed (ROCE) | -37.77% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -579,526 |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.35% in the last 52 weeks. The beta is 1.54, so Bioceltix's price volatility has been higher than the market average.
| Beta (5Y) | 1.54 |
| 52-Week Price Change | +10.35% |
| 50-Day Moving Average | 85.06 |
| 200-Day Moving Average | 74.05 |
| Relative Strength Index (RSI) | 72.05 |
| Average Volume (20 Days) | 6,959 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.38M |
| Operating Income | -15.75M |
| Pretax Income | -15.59M |
| Net Income | -15.65M |
| EBITDA | -15.27M |
| EBIT | -15.75M |
| Earnings Per Share (EPS) | -3.83 |
Balance Sheet
The company has 38.20 million in cash and 948,264 in debt, giving a net cash position of 37.25 million or 7.57 per share.
| Cash & Cash Equivalents | 38.20M |
| Total Debt | 948,264 |
| Net Cash | 37.25M |
| Net Cash Per Share | 7.57 |
| Equity (Book Value) | 41.43M |
| Book Value Per Share | 8.41 |
| Working Capital | 38.99M |
Cash Flow
In the last 12 months, operating cash flow was -18.49 million and capital expenditures -25,623, giving a free cash flow of -18.52 million.
| Operating Cash Flow | -18.49M |
| Capital Expenditures | -25,623 |
| Free Cash Flow | -18.52M |
| FCF Per Share | -3.76 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bioceltix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.65% |
| Shareholder Yield | -7.65% |
| Earnings Yield | -3.34% |
| FCF Yield | -3.96% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |